rs886039551
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PM1PM2PM5PP3_StrongPP5_Very_Strong
The NM_003242.6(TGFBR2):c.1336G>A(p.Asp446Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D446Y) has been classified as Pathogenic.
Frequency
Consequence
NM_003242.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TGFBR2 | ENST00000295754.10 | c.1336G>A | p.Asp446Asn | missense_variant | 5/7 | 1 | NM_003242.6 | ENSP00000295754.5 | ||
TGFBR2 | ENST00000359013.4 | c.1411G>A | p.Asp471Asn | missense_variant | 6/8 | 1 | ENSP00000351905.4 | |||
TGFBR2 | ENST00000672866.1 | n.2932G>A | non_coding_transcript_exon_variant | 5/7 | ||||||
TGFBR2 | ENST00000673203.1 | n.214G>A | non_coding_transcript_exon_variant | 1/3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 24, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 446 of the TGFBR2 protein (p.Asp446Asn). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with aortic dilation or Loeys-Dietz syndrome (PMID: 16251899, 18781618, 19006214, 21484991, 22095581, 22259224, 23884466, 24792536). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 265447). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (Invitae) indicates that this missense variant is expected to disrupt TGFBR2 function. This variant disrupts the p.Asp446 amino acid residue in TGFBR2. Other variant(s) that disrupt this residue have been observed in individuals with TGFBR2-related conditions (PMID: 21484991), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 12, 2017 | The p.D446N pathogenic mutation (also known as c.1336G>A), located in coding exon 5 of the TGFBR2 gene, results from a G to A substitution at nucleotide position 1336. The aspartic acid at codon 446 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been detected in multiple unrelated individuals with Loeys-Dietz syndrome (LDS), reported as occurring de novo in a few cases, and described to segregate with disease in a few families (Disabella E et al. Eur. J. Hum. Genet., 2006 Jan;14:34-8; Stheneur C et al. Hum. Mutat., 2008 Nov;29:E284-95; Watanabe Y et al. Am. J. Med. Genet. A, 2008 Dec;146A:3070-4; Sousa SB et al. Am. J. Med. Genet. A, 2011 May;155A:1178-83; Ben Amor IM et al. J. Bone Miner. Res., 2012 Mar;27:713-8; Frischmeyer-Guerrerio PA et al. Sci Transl Med, 2013 Jul;5:195ra94; Longmuir SQ et al. J AAPOS, 2014 Jun;18:288-90). Internal structural analysis suggested that this alteration would destabilize the structure of the C-terminal lobe of the kinase domain. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Aug 22, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 09, 2023 | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23884466, 18781618, 22095581, 16835936, 16251899, 22259224, 32352226, 24792536, 32152251, 19006214, 30219046) - |
Loeys-Dietz syndrome 1 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | Sep 30, 2016 | - - |
Loeys-Dietz syndrome 2 Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | Centre of Medical Genetics, University of Antwerp | Mar 01, 2021 | PM2, PS1, PM1, PP1 - |
TGFBR2-related disorder Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 01, 2022 | The TGFBR2 c.1336G>A variant is predicted to result in the amino acid substitution p.Asp446Asn. This is a recurrent de novo variant that has been reported in multiple individuals with Loeys-Dietz syndrome (Ben Amor et al. 2012. PubMed ID: 22095581; Jani et al. 2020. PubMed ID: 32152251; Stheneur et al. 2008. PubMed ID: 18781618). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as likely pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at